Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia, human C‑peptide production and mature GSIS, supported by scalable bioreactor-based manufacturingInvestigational New Drug (IND)-enabling studies on track to initiate by year-end 2025; IND submission planned as early as 2026 PHILADELPHIA, Nov. 13, 2025 (GLOBE N ...